Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Aug-24 5:58 PM View:  | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Exercise | 37,500 | -- | -- | 5% 727.41K to 764.91K | |
| 22-Aug-24 6:00 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Exercise | 11,250 | -- | -- | 9% 123.73K to 134.98K | |
| 22-Aug-24 5:58 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Sale | 13,898 | $1.23 | $17,082.00 | (2%) 764.91K to 751.01K | |
| 22-Aug-24 6:01 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Exercise | 11,250 | -- | -- | 7% 168.58K to 179.83K | |
| 22-Aug-24 6:01 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Exercise | 11,250 | -- | -- | 9% 119.67K to 130.92K | |
| 22-Aug-24 5:59 PM View: | Ogden Christopher Chief Financial Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Exercise | 6,875 | -- | -- | 7% 103.19K to 110.06K | |
| 22-Aug-24 6:00 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Sale | 4,181 | $1.23 | $5,138.87 | (3%) 134.98K to 130.8K | |
| 22-Aug-24 6:01 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Sale | 4,181 | $1.23 | $5,138.87 | (2%) 179.83K to 175.65K | |
| 22-Aug-24 6:01 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Sale | 4,181 | $1.23 | $5,138.87 | (3%) 130.92K to 126.74K | |
| 22-Aug-24 5:59 PM View: | Ogden Christopher Chief Financial Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Aug-24 | Option Sale | 1,984 | $1.23 | $2,438.53 | (2%) 110.06K to 108.08K | |
| 14-Jun-24 4:24 PM View: | Ogden Christopher Chief Financial Officer | Cytomx Therapeutics, Inc. (CTMX) | 12-Jun-24 | Grant | 17,500 | -- | -- | 20% 85.69K to 103.19K | |
| 28-Mar-24 7:12 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 26-Mar-24 | Option Exercise | 109,768 | $1.57 | $172,874.00 | 18% 617.64K to 727.41K | |
| 21-Mar-24 4:41 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 19-Mar-24 | Sale | 5,268 | $2.09 | $10,986.40 | (4%) 123.0K to 117.73K | |
| 21-Mar-24 4:37 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 19-Mar-24 | Sale | 12,795 | $2.09 | $26,684.00 | (7%) 181.37K to 168.58K | |
| 21-Mar-24 4:36 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 19-Mar-24 | Sale | 6,562 | $2.09 | $13,685.10 | (5%) 124.3K to 117.74K | |
| 21-Mar-24 4:38 PM View: | Ogden Christopher SVP, Finance and Accounting | Cytomx Therapeutics, Inc. (CTMX) | 19-Mar-24 | Sale | 2,971 | $2.09 | $6,196.02 | (3%) 88.66K to 85.69K | |
| 21-Mar-24 4:40 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 19-Mar-24 | Sale | 20,223 | $2.09 | $42,175.10 | (3%) 637.86K to 617.64K | |
| 19-Jan-24 8:38 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 18-Jan-24 | Grant | 26,250 | -- | -- | 17% 155.12K to 181.37K | |
| 19-Jan-24 8:37 PM View: | Chu Yu-Waye Chief Medical Officer | Cytomx Therapeutics, Inc. (CTMX) | 18-Jan-24 | Grant | 26,250 | -- | -- | 100% 0 to 26.25K | |
| 19-Jan-24 8:40 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 18-Jan-24 | Grant | 30,000 | -- | -- | 32% 94.3K to 124.3K | |
| 19-Jan-24 8:41 PM View: | Ogden Christopher SVP, Finance and Accounting | Cytomx Therapeutics, Inc. (CTMX) | 18-Jan-24 | Grant | 40,000 | -- | -- | 82% 48.66K to 88.66K | |
| 19-Jan-24 8:44 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 18-Jan-24 | Grant | 90,000 | -- | -- | 16% 547.86K to 637.86K | |
| 19-Jan-24 8:43 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 18-Jan-24 | Grant | 25,000 | -- | -- | 26% 98.0K to 123.0K | |
| 22-Dec-23 4:16 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 20-Dec-23 | Sale | 13,551 | $1.38 | $18,709.90 | (2%) 561.41K to 547.86K | |
| 22-Dec-23 4:11 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 20-Dec-23 | Sale | 4,077 | $1.38 | $5,629.11 | (4%) 102.07K to 98.0K | |
| 22-Dec-23 4:14 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Dec-23 | Sale | 4,077 | $1.38 | $5,628.30 | (3%) 159.2K to 155.12K | |
| 22-Dec-23 4:12 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Dec-23 | Sale | 4,077 | $1.38 | $5,628.30 | (4%) 98.38K to 94.3K | |
| 22-Dec-23 4:10 PM View: | Ogden Christopher SVP, Finance and Accounting | Cytomx Therapeutics, Inc. (CTMX) | 20-Dec-23 | Sale | 1,990 | $1.38 | $2,747.39 | (4%) 50.65K to 48.66K | |
| 19-Dec-23 7:55 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 17-Dec-23 | Option Exercise | 11,250 | -- | -- | 12% 90.82K to 102.07K | |
| 19-Dec-23 7:54 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 17-Dec-23 | Option Exercise | 11,250 | -- | -- | 8% 147.95K to 159.2K | |
| 19-Dec-23 7:56 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 17-Dec-23 | Option Exercise | 11,250 | -- | -- | 13% 87.13K to 98.38K | |
| 19-Dec-23 7:58 PM View: | Ogden Christopher SVP, Finance and Accounting | Cytomx Therapeutics, Inc. (CTMX) | 17-Dec-23 | Option Exercise | 6,875 | -- | -- | 16% 43.77K to 50.65K | |
| 19-Dec-23 7:57 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 17-Dec-23 | Option Exercise | 37,500 | -- | -- | 7% 523.91K to 561.41K | |
| 22-Sep-23 7:13 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 22-Sep-23 | Sale | 14,601 | $1.30 | $18,987.10 | (3%) 538.51K to 523.91K | |
| 22-Sep-23 7:12 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 22-Sep-23 | Sale | 5,486 | $1.30 | $7,135.09 | (6%) 86.09K to 80.61K | |
| 22-Sep-23 7:16 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 22-Sep-23 | Sale | 4,119 | $1.30 | $5,355.94 | (3%) 152.07K to 147.95K | |
| 22-Sep-23 7:15 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 22-Sep-23 | Sale | 4,119 | $1.30 | $5,355.94 | (5%) 88.18K to 84.06K | |
| 22-Sep-23 7:16 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Sep-23 | Grant | 11,250 | -- | -- | 8% 140.82K to 152.07K | |
| 22-Sep-23 7:15 PM View: | Landau Jeffrey B Chief Business Officer | Cytomx Therapeutics, Inc. (CTMX) | 20-Sep-23 | Grant | 11,250 | -- | -- | 15% 76.93K to 88.18K | |
| 22-Sep-23 7:12 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 20-Sep-23 | Grant | 15,000 | -- | -- | 21% 71.09K to 86.09K | |
| 22-Sep-23 7:13 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 20-Sep-23 | Grant | 40,000 | -- | -- | 8% 498.51K to 538.51K | |
| 23-May-23 4:52 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 19-May-23 | Option Exercise | 16,535 | $1.57 | $26,041.00 | 3% 481.98K to 498.51K | |
| 31-Mar-23 7:56 PM View: | Jones Elaine V Director | Cytomx Therapeutics, Inc. (CTMX) | 29-Mar-23 | Private Purchase | 5,000 | $1.55 | $7,750.00 | 3521% 0.14K to 5.14K | |
| 29-Mar-23 7:54 PM View: | Belvin Marcia SVP, Chief Scientific Officer | Cytomx Therapeutics, Inc. (CTMX) | 22-Mar-23 | Grant | 60,000 | -- | -- | 74% 80.82K to 140.82K | |
| 20-Mar-23 6:43 PM View: | Peterson Amy C. EVP, Chief Development Officer | Cytomx Therapeutics, Inc. (CTMX) | 16-Mar-23 | Sale | 4,257 | $1.98 | $8,424.60 | (7%) 62.69K to 58.43K | |
| 20-Mar-23 6:43 PM View: | Campoy Carlos Chief Financial Officer | Cytomx Therapeutics, Inc. (CTMX) | 16-Mar-23 | Sale | 1,748 | $1.98 | $3,459.47 | (4%) 39.97K to 38.22K | |
| 20-Mar-23 6:43 PM View: | Rowland Lloyd A General Counsel | Cytomx Therapeutics, Inc. (CTMX) | 16-Mar-23 | Sale | 2,037 | $1.98 | $4,031.22 | (3%) 73.13K to 71.09K | |
| 20-Mar-23 6:43 PM View: | McCarthy Sean A. CEO Director | Cytomx Therapeutics, Inc. (CTMX) | 16-Mar-23 | Sale | 7,121 | $1.88 | $13,391.00 | (1%) 489.1K to 481.98K | |
| 20-Mar-23 6:43 PM View: | Landau Jeffrey B Chief Financial Officer | Cytomx Therapeutics, Inc. (CTMX) | 16-Mar-23 | Sale | 1,477 | $1.98 | $2,923.28 | (2%) 78.41K to 76.93K | |
| 20-Mar-23 6:43 PM View: | Ogden Christopher SVP, Finance and Accounting | Cytomx Therapeutics, Inc. (CTMX) | 16-Mar-23 | Sale | 516 | $1.98 | $1,021.32 | (1%) 38.29K to 37.77K |
